ALB and cancer: More specifically, those approved for cancer treatment are described in a review by Tracey et al. [9] and include (i) liposomes for the delivery of doxorubicin (Doxil®, Myocet®), daunorubicin (DanuoXome®), cytarabine (DepoCyt®), mifamurtide (MEPACT®), vincristine sulphate ((Marqibo®), irinotecan (Onivyde®) or a combination of cytarabine and daunorubicin (Vyxeos®), (ii) albumin-based nanoparticles (Abraxane®), and (iii) lipid micelles (Apealea®) for the delivery of paclitaxel.